Meridian Biopharmaceuticals and greenovation Biotech GmbH have recently signed a licensing agreement regarding the use of greenovation´s bryotechnology for Meridian´s development of MB 314, a glyco-modified second generation antibody with optimized effector functions. The German Biotech company greenovation is specialized in plant (moss) expression systems and is owner of the relevant IP. Greenovation will also develop the production process up to production of clinical grade - under GMP condition produced - material.
Meridian Biopharmaceuticals has established a tight interaction with Quality Systems Consulting, QSC GmbH regarding Quality Assurance & Quality Control aspects.
Auditreu provides controlling, accounting, tax consulting and payroll to Meridian Biopharmaceuticals.